Background: Recent studies have shown that some vaccines have beneficial effects that cannot be explained solely by the prevention of their respective targeted disease(s). Methods: We used the MarketScan US Commercial Claims Databases for 2005 to 2014 to assess the risk of hospital admission for nontargeted infectious (NTI) diseases in children aged 16 through 24 months according to the last vaccine type (live and/or inactivated). We included children continuously enrolled within a month of birth through 15 months who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age. We used Cox regression to estimate hazard ratios (HRs), stratifying by birthdate to control for age, year, and seasonality and adjusting for sex, chronic diseases, prior hospitalizations, number of outpatient visits, region of residence, urban/rural area of domicile, prematurity, low birth weight, and mother's age. Results: 311663 children were included. In adjusted analyses, risk of hospitalization for NTI from ages 16 through 24 months was reduced for those who received live vaccine alone compared with inactivated alone or concurrent live and inactivated vaccines (HR, 0.50; 95% confidence interval [CI], 0.43, 0.57 and HR, 0.78; 95% CI, 0.67, 0.91, respectively) and for those who received live and inactivated vaccines concurrently compared with inactivated-only (HR, 0.64; 95% CI, 0.58, 0.70). Conclusions: We found lower risk of NTI disease hospitalizations from age 16 through 24 months among children whose last vaccine received was live compared with inactivated vaccine, as well as concurrent receipt compared with inactivated vaccine. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Recent studies have shown that some vaccines have beneficial effects that cannot be explained solely by the prevention of their respective targeted disease(s). Methods: We used the MarketScan US Commercial Claims Databases for 2005 to 2014 to assess the risk of hospital admission for nontargeted infectious (NTI) diseases in children aged 16 through 24 months according to the last vaccine type (live and/or inactivated). We included children continuously enrolled within a month of birth through 15 months who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age. We used Cox regression to estimate hazard ratios (HRs), stratifying by birthdate to control for age, year, and seasonality and adjusting for sex, chronic diseases, prior hospitalizations, number of outpatient visits, region of residence, urban/rural area of domicile, prematurity, low birth weight, and mother's age. Results: 311663 children were included. In adjusted analyses, risk of hospitalization for NTI from ages 16 through 24 months was reduced for those who received live vaccine alone compared with inactivated alone or concurrent live and inactivated vaccines (HR, 0.50; 95% confidence interval [CI], 0.43, 0.57 and HR, 0.78; 95% CI, 0.67, 0.91, respectively) and for those who received live and inactivated vaccines concurrently compared with inactivated-only (HR, 0.64; 95% CI, 0.58, 0.70). Conclusions: We found lower risk of NTI disease hospitalizations from age 16 through 24 months among children whose last vaccine received was live compared with inactivated vaccine, as well as concurrent receipt compared with inactivated vaccine. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Tamara D Simon; Mary Lawrence Cawthon; Susan Stanford; Jean Popalisky; Dorothy Lyons; Peter Woodcox; Margaret Hood; Alex Y Chen; Rita Mangione-Smith Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Jason M Glanz; Sophia R Newcomer; Komal J Narwaney; Simon J Hambidge; Matthew F Daley; Nicole M Wagner; David L McClure; Stan Xu; Ali Rowhani-Rahbar; Grace M Lee; Jennifer C Nelson; James G Donahue; Allison L Naleway; James D Nordin; Marlene M Lugg; Eric S Weintraub Journal: JAMA Pediatr Date: 2013-03-01 Impact factor: 16.193
Authors: Helen S Goodridge; S Sohail Ahmed; Nigel Curtis; Tobias R Kollmann; Ofer Levy; Mihai G Netea; Andrew J Pollard; Reinout van Crevel; Christopher B Wilson Journal: Nat Rev Immunol Date: 2016-05-09 Impact factor: 53.106
Authors: Peter Aaby; Christine Benn; Jens Nielsen; Ida Maria Lisse; Amabelia Rodrigues; Henrik Ravn Journal: BMJ Open Date: 2012-05-22 Impact factor: 2.692
Authors: Julian P T Higgins; Karla Soares-Weiser; José A López-López; Artemisia Kakourou; Katherine Chaplin; Hannah Christensen; Natasha K Martin; Jonathan A C Sterne; Arthur L Reingold Journal: BMJ Date: 2016-10-13
Authors: Barbara H Bardenheier; Michael M McNeil; A Patricia Wodi; Janet M McNicholl; Frank DeStefano Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Jason M Glanz; Sophia R Newcomer; Matthew F Daley; Frank DeStefano; Holly C Groom; Michael L Jackson; Bruno J Lewin; Natalie L McCarthy; David L McClure; Komal J Narwaney; James D Nordin; Ousseny Zerbo Journal: JAMA Date: 2018-03-06 Impact factor: 56.272
Authors: Peter Aaby; Christine Stabell Benn; Katie L Flanagan; Sabra L Klein; Tobias R Kollmann; David J Lynn; Frank Shann Journal: Nat Rev Immunol Date: 2020-05-27 Impact factor: 53.106